LB 933 protects Nebraska healthcare practitioners who recommend medical cannabis under the Nebraska Medical Cannabis Patient Protection Act. The bill shields doctors, nurses, and other licensed providers from disciplinary action - including license penalties or civil fines - when they provide a written recommendation or state in their professional opinion that a patient may benefit from cannabis for medical treatment. This applies specifically to recommendations for conditions like chronic pain or nausea, not general cannabis use. The law directly affects healthcare professionals who interact with medical cannabis patients in Nebraska.
LB 955 allows pharmacists in Nebraska to form written practice agreements with physician assistants (PAs) who work under collaborative agreements with physicians. These agreements enable PAs to coordinate with pharmacists to provide pharmaceutical care under specific written protocols for monitored or initiated therapies. The bill requires pharmacists to notify both the Pharmacy Board and the PA's licensing board about agreements, include signed protocols, and review agreements every two years. This change directly affects pharmacists, PAs, and their supervising physicians by creating a formalized process for collaborative patient care.
LB 322 increases penalties for assaulting specific professionals while they are working. It makes assault on pharmacists, healthcare workers (including hospital/clinic staff), and emergency responders a higher felony classification when committed during their duties at pharmacies, hospitals, or clinics. The bill defines "pharmacist" as a state-licensed pharmacy practitioner and "health care professional" to include all employees at healthcare facilities. This amendment enhances existing assault penalties for these targeted groups without creating new prohibitions. The bill is currently postponed indefinitely in Nebraska's legislative process.
This bill eliminates numerous state advisory groups, boards, and commissions - including the Climate Assessment Response Committee, Women's Health Initiative Advisory Council, and Palliative Care Act - and removes their funding. It also modifies department responsibilities, such as adjusting the Board of Mental Health Practice and the Department of Health and Human Services. The bill specifically terminates the Whiteclay Public Health Emergency Task Force and streamlines overlapping government structures by repealing obsolete provisions. These changes aim to simplify state agency operations by removing redundant entities and consolidating functions.
LB 326 amends Nebraska's insurance laws to update definitions and procedures under the Unfair Insurance Trade Practices Act and related statutes. It redefines key terms like "insurer" and "customer," changes the Director of Insurance's authority, and updates rules for claims, settlements, and annual reporting. The bill specifically eliminates the Health Insurance Access Act and Health Care Purchasing Pool Act, removing those frameworks from state law. These changes primarily affect insurance companies, consumers purchasing insurance, and the Nebraska Department of Insurance.
Nebraska's LB 168 (signed April 9, 2025) adopts the 340B Contract Pharmacy Protection Act to protect access to federally discounted drugs. It prohibits drug manufacturers from restricting 340B drug deliveries to authorized locations (like contract pharmacies) or demanding extra data (such as patient records) beyond federal requirements. The law directly affects safety-net hospitals, clinics, and other 340B entities that rely on discounted drugs, as well as drug manufacturers and distributors. It ensures these providers can continue using 340B discounts without unnecessary barriers imposed by manufacturers.
